You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行报告》麦格理升药明康德(02359.HK)目标价34%至203.92元 评级「跑赢大市」
阿思达克 04-13 15:54
麦格理发表研究报告,指全球CRO(医药研发合同外包服务机构)同业对今年审慎乐观,基本需求强劲,指临床中心重启,志愿者招募改善,及随着遥距及数码化策略落地,已适应疫情。CRO客户所获得资金仍强劲,带来持续需求,特别是早期产品及复杂科技。

报告称,中国CRO全球市占仍十分小,倘持续渗透全球市场,意味长远增长空间庞大。麦格理表示,药明康德(02359.HK)药品发现服务属全球顶尖之列,在传统CRO中脱颖而出,在强劲行业资金状况下,拥更直接增长机遇。该行上调其今明两年每股盈测8%及7%,目标价升34%,由152.27元升至203.92元,评级「跑赢大市」。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account